Eyepoint Pharmaceuticals’ (EYPT) Underweight Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their underweight rating on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a research report sent to investors on Tuesday, Marketbeat.com reports.

Other analysts also recently issued reports about the stock. Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price objective on the stock. Citigroup decreased their target price on shares of Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a research report on Tuesday, August 18th. Mizuho restated a “neutral” rating and issued a $0.50 price target on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Jefferies Financial Group lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price target on the stock. in a research note on Monday. Finally, Weiss Ratings raised Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Eyepoint Pharmaceuticals has an average rating of “Hold” and an average target price of $21.85.

Eyepoint Pharmaceuticals Stock Performance

EYPT stock opened at $0.43 on Tuesday. Eyepoint Pharmaceuticals has a 1 year low of $0.39 and a 1 year high of $19.11. The stock has a market capitalization of $36.91 million, a price-to-earnings ratio of -0.11 and a beta of 1.67. The stock’s fifty day moving average is $3.99 and its two-hundred day moving average is $10.03.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. The firm had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, analysts predict that Eyepoint Pharmaceuticals will post -3.50 EPS for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System boosted its position in shares of Eyepoint Pharmaceuticals by 2,158.3% during the 1st quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock valued at $1,355,000 after purchasing an additional 100,447 shares in the last quarter. Commodore Capital LP acquired a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter worth approximately $36,414,000. Walleye Capital LLC acquired a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter worth approximately $3,869,000. Swiss National Bank bought a new stake in shares of Eyepoint Pharmaceuticals in the 1st quarter worth approximately $1,900,000. Finally, Stempoint Capital LP raised its holdings in shares of Eyepoint Pharmaceuticals by 129.1% in the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after purchasing an additional 456,915 shares in the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its Q3 2027 EPS forecast to $0.45 from a projected loss of $0.45, suggesting the analyst still sees a potential path to profitability in the longer term. However, the firm maintained a Neutral rating. HC Wainwright estimates
• Neutral Sentiment: Several firms maintained cautious views: HC Wainwright reaffirmed Neutral, Mizuho assigned Neutral, and Laidlaw reaffirmed Hold. These ratings indicate limited conviction in a near-term recovery following the clinical setback. HC Wainwright rating Mizuho rating Laidlaw rating
• Neutral Sentiment: Large call-option activity suggests some traders are positioning for a rebound, but options activity is speculative and does not change the company’s fundamental outlook. EyePoint call options
• Negative Sentiment: HC Wainwright reduced its Q3 2026 EPS estimate to a loss of $0.85 from $0.60 and cut its FY2026 estimate to a loss of $3.40 from $3.15, reflecting worsening near-term expectations. Revised EPS estimates
• Negative Sentiment: JPMorgan issued an Underweight rating, while Jefferies and Guggenheim downgraded the stock, adding further institutional pressure after the failed LUCIA trial. JPMorgan rating Jefferies downgrade Guggenheim downgrade
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities claims related to the LUCIA trial disclosure and the resulting shareholder losses. The investigation adds legal and reputational risk, although it does not establish wrongdoing. Levi & Korsinsky investigation

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.